Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $22.28M
• Dividend Yield: N/A
• Average Volume (3M): 25.96K
• Price to Earnings (P/E): 4.1
• Beta (1Y): 1.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: General
• Sector Strength: N/A
• Industry: Advertising Agencies
• EPS (TTM): 0.01
• Shares Outstanding: 2,131,595
• 10 Day Avg. Volume: 17,780
• 30 Day Avg. Volume: 25,958
• PEG Ratio: -5.00
• Price to Book (P/B): 5.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.89
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 10.00T>
• Enterprise Value/Ebitda: 8.17
• 1Y Price Target: $1.00
• Price Target Upside: -26.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: $1.50 ▲(10.29%Upside)

The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. The company was founded in 2018 and is based in Beijing, China.

How the Company Makes Money

Haoxi Health Technology generates revenue through multiple streams, including the sale of medical devices and health monitoring systems directly to healthcare providers and institutions. Additionally, the company offers subscription-based services for its telemedicine platforms, which allow patients to consult with healthcare professionals remotely. Partnerships with hospitals and clinics play a significant role in driving sales and expanding market reach. Furthermore, HAO may benefit from government contracts and grants aimed at advancing health technology solutions, contributing to its overall earnings.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited shows strong revenue growth with a substantial increase from $28.2M in 2023 to $48.5M in 2024, indicating a positive trajectory. However, the company faces challenges with cash flow generation and profit margins, needing improvements in these areas to sustain long-term growth.

Income Statement

Haoxi Health Technology Limited shows strong revenue growth with a substantial increase from $28.2M in 2023 to $48.5M in 2024, marking a growth rate of 71.88%. The gross profit margin in 2024 stands at 5.67%, indicating an improvement over previous years but still relatively low. The net profit margin for 2024 is 2.66%, demonstrating profitability but with room for improvement. EBIT and EBITDA margins are 3.54% and 3.68%, respectively, showing stability in earnings.

Balance Sheet

The company exhibits a solid equity position with a positive stockholders' equity of $11.27M in 2024, a significant turnaround from negative equity in earlier years. However, the debt-to-equity ratio is 0.11, indicating low leverage but also reflecting a cautious approach. The equity ratio is relatively strong at 72.69%, showcasing financial stability, though the overall asset base remains modest.

Cash Flow

Cash flow performance is mixed, with negative free cash flow of -$802,943 in 2024, although showing improvement from the previous year. The operating cash flow to net income ratio is -0.58, suggesting that operating activities are not yet fully supporting net income generation. Despite this, the company has improved its financing cash flow, indicating potential for future investments.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.52M	28.23M	16.16M	12.85M
Gross Profit	2.75M	2.06M	648.72K	605.58K
EBITDA	1.79M	1.22M	271.77K	330.96K
Net Income	1.29M	969.75K	244.59K	304.06K
Balance Sheet
Total Assets	15.51M	4.46M	542.99K	2.81M
Cash, Cash Equivalents and Short-Term Investments	6.66M	1.20M	293.51K	55.89K
Total Debt	1.20M	897.61K	505.40K	1.15M
Total Liabilities	4.23M	2.90M	2.01M	4.74M
Stockholders Equity	11.27M	1.57M	-1.47M	-1.93M
Cash Flow
Free Cash Flow	-802.94K	-917.63K	―	2.65M
Operating Cash Flow	-747.58K	-872.13K	-675.36K	2.65M
Investing Cash Flow	-3.13M	-45.50K	―	―
Financing Cash Flow	9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.35, and below the 200-day MA of 2.46, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 38.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAO	68 Neutral	$22.28M	4.10	2.92%	―	―	―
WIMI	61 Neutral	$32.90M	6.60	8.21%	―	-8.74%	―
MCHX	61 Neutral	$85.17M	―	-16.55%	―	-2.67%	21.65%
INUV	60 Neutral	$72.97M	―	-34.39%	―	18.20%	50.08%
Sector *	56 Neutral	$6.34B	18.40	-28.96%	6.02%	10.40%	-36.04%
FLNT	45 Neutral	$47.33M	―	-123.16%	―	-15.07%	33.40%
DRCT	41 Neutral	$10.06M	―	-320.07%	―	-69.54%	-19665.56%